MediciNova Inc（MNOV）の株式分析MNOVMediciNova Inc

MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

MediciNova Inc is a good buy right now due to its recent clinical trial successes and positive analyst ratings. The current price is $1.435, significantly below the analyst price targets of $6 and $10, indicating substantial upside potential. Additionally, the gross margin has dramatically improved to 69.31% in Q2 2026, showcasing operational efficiency. However, the main risk is the ongoing negative net income, which was -$2,314,139 in Q2 2026, reflecting the financial challenges the company still faces.

1 analysts cover MNOV: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.00.